MK-677 Restored Growth Hormone to Young-Adult Levels and Added Lean Mass. The Strength Never Showed Up.
MK-677, known chemically as ibutamoren, gets discussed online as an oral growth hormone pill, which is close enough to be misleading. It is not growth hormone and it is not a peptide injection. It is an orally active small molecule that mimics ghrelin, binds the growth hormone secretagogue receptor, and prompts the pituitary to release more of its own growth hormone in a pulsing pattern that looks broadly natural. Merck developed it decades ago and ran real trials, which is unusual for a compound now sold mostly through research-chemical channels. Those trials are the reason MK-677 is worth writing about carefully rather than either hyping or dismissing. They show a drug that does exactly what its mechanism predicts on some measures and conspicuously fails to deliver on the one most people actually want. Growth hormone and IGF-1 go up and stay up. Lean body mass goes up. Appetite goes up. Fasting blood sugar goes up. Muscle strength and physical function, the outcomes that would justify taking it for performance or healthy aging, did not improve to a degree the studies could call real. This article walks through what the published data reported, where it is strong, where it is thin, and why building mass and building strength came apart. It is educational background on trial results, not medical advice, a protocol, or a recommendation to take or avoid anything.
The Short Version: What the MK-677 Trials Actually Found
MK-677 is an orally active growth hormone secretagogue, meaning it prompts the body to release more of its own growth hormone rather than supplying hormone from outside. In the main two-year trial in healthy older adults, MK-677 at 25 milligrams daily raised serum IGF-1 by roughly 84 percent against 17 percent on placebo, restoring the hormone to levels typical of young adults. The same trial reported a gain of about 1.1 kilograms of fat-free mass on MK-677 while the placebo group lost about 0.5 kilograms. Muscle strength and physical performance measures did not improve significantly, so the extra lean mass did not translate into measurable function. Fasting blood glucose rose by roughly 5 milligrams per decilitre and insulin sensitivity declined, which is the predictable metabolic cost of keeping growth hormone elevated. A separate trial in patients recovering from hip fracture found no improvement in functional recovery. MK-677 is not approved by the FDA for any use and is sold as a research chemical rather than a medicine.
What Is MK-677 and How Does It Actually Work?
MK-677 is a non-peptide compound that activates the growth hormone secretagogue receptor, the same receptor the stomach hormone ghrelin uses. By imitating ghrelin at that receptor, MK-677 nudges the hypothalamus and pituitary to release growth hormone in bursts and it also blunts somatostatin, the brake that normally shuts growth hormone release down. The net effect is more growth hormone released across the day, which the liver converts into higher circulating IGF-1. Two features make MK-677 distinctive among growth hormone tools. It is orally active, so it works as a tablet rather than an injection, which is why it gets marketed as a growth hormone pill. And its action lasts long enough to support once-daily dosing, so a single dose keeps growth hormone and IGF-1 elevated around the clock rather than in a brief spike. That constant elevation is central to both its appeal and its problems, because growth hormone was never meant to sit high all day. Because MK-677 works upstream on the body's own machinery, it depends on a functioning pituitary and does not replace growth hormone in people who cannot make it.
The One Thing MK-677 Reliably Does
Mean rise in serum IGF-1 over the two-year Nass trial in 65 healthy adults aged 60 to 81. Oral MK-677 at 25 mg daily raised IGF-1 by roughly 84 percent against 17 percent on placebo, restoring the hormone to levels typical of young adults. This is the most consistent and best-documented effect of the drug, and it is a genuine result from a randomized, placebo-controlled study.
How Much Does MK-677 Raise Growth Hormone and IGF-1?
The IGF-1 response is the most reliable and best-documented thing MK-677 does. In the two-year randomized trial by Nass and colleagues, published in the Annals of Internal Medicine in 2008, 65 healthy adults aged 60 to 81 took either MK-677 at 25 milligrams daily or placebo. IGF-1 rose by about 84 percent on the drug against about 17 percent on placebo, which brought the older participants' IGF-1 into the range normally seen in healthy young adults. Growth hormone secretion increased alongside it. This is a large, consistent hormonal effect from a properly controlled study, and it is the part of the MK-677 story that is genuinely solid. The important caveat is that raising IGF-1 is a means, not an end. IGF-1 is a signaling molecule, and pushing it up only matters if it produces something a person can feel or use, such as more strength, better recovery, or a longer healthspan. The trials measured whether it did, and that is where the picture gets more complicated.
Lean Mass Went Up
Change in fat-free mass over the same two years. The MK-677 group gained about 1.1 kilograms of fat-free mass while the placebo group lost about 0.5 kilograms, a difference the trial reported as statistically significant. Fat-free mass includes muscle, water and other lean tissue, and some of the early gain reflects the fluid retention that ghrelin-mimetic drugs tend to cause. The dashed line marks no change from baseline.
Does MK-677 Build Muscle?
MK-677 increased fat-free mass, but that is not the same as building usable muscle. In the Nass trial the MK-677 group gained roughly 1.1 kilograms of fat-free mass over two years while the placebo group lost about half a kilogram, a difference the authors reported as statistically significant. Fat-free mass is everything in the body that is not fat, which includes muscle but also water and connective tissue. Growth hormone and ghrelin-mimetic drugs both promote fluid retention, so a portion of the early gain on MK-677 reflects retained water rather than new contractile muscle. Even setting the water aside, a gain of about a kilogram of lean tissue spread across two years is modest, and it sat well below what the enthusiastic marketing around the compound tends to imply. The honest summary is that MK-677 shifts body composition in the direction of more lean mass and does so measurably, while the size of that shift is small and its composition is not purely muscle. Whether that lean mass did any work is the question the next finding answers.
What Reached Significance, and What Did Not
The four outcomes that matter most to anyone considering MK-677 for strength, scored by whether the difference from placebo reached statistical significance. IGF-1 and fat-free mass cleared that bar. Muscle strength and physical performance measures such as gait speed and stair climbing did not, even though several of them improved numerically. A tall teal bar means the effect held up statistically; a short grey bar means it did not.
If It Adds Lean Mass, Why Didn't Strength Improve?
The extra lean mass did not translate into measurable strength or function, and that disconnect is the single most important finding about MK-677. In the Nass trial, muscle strength and lower-extremity performance measures such as gait speed and stair climbing did not improve to a statistically significant degree, even though participants gained fat-free mass. Some function scores drifted in a favorable direction, but none crossed the line that separates a real effect from noise. This matters because mass and strength are different things. Muscle gets stronger primarily through neural adaptation and the growth of force-producing fibers under load, which is what resistance training drives. Adding lean tissue without training it, and adding a meaningful fraction of that tissue as retained water, is not a recipe for force production. MK-677 raises the raw material of muscle and does nothing to make a person use it. For anyone considering the compound to get stronger or more capable rather than simply to change a number on a body composition scan, this is the result that should carry the most weight, because it is the outcome the drug was supposed to deliver and did not.
What Reached Significance, and What Did Not
The four outcomes that matter most to anyone considering MK-677 for strength, scored by whether the difference from placebo reached statistical significance. IGF-1 and fat-free mass cleared that bar. Muscle strength and physical performance measures such as gait speed and stair climbing did not, even though several of them improved numerically. A tall teal bar means the effect held up statistically; a short grey bar means it did not.
What Did the Hip-Fracture Trial Find?
A dedicated functional trial in frail patients found no recovery benefit from MK-677. Beyond the healthy-aging study, MK-677 was tested in a multicenter, randomized, placebo-controlled phase IIb trial in older patients recovering from hip fracture, a population where any real gain in strength or physical function would show up clearly and matter enormously. The rationale was sound, since these patients are losing muscle and struggling to regain the ability to walk and climb stairs, exactly the setting where a drug that adds lean mass might help. It did not produce a meaningful improvement in functional recovery. This is a useful check on the healthy-aging data, because it tested the drug where the stakes and the potential to detect a benefit were both high. Two separate trials, in two different populations, converged on the same conclusion. MK-677 changes hormones and body composition without reliably changing what a person can do. That consistency is more informative than any single study, and it is the reason the strength claims that circulate around the compound are not supported by the trials that were actually run.
Does MK-677 Raise Blood Sugar and Hurt Insulin Sensitivity?
Yes, and this is the tradeoff that comes bundled with the growth hormone elevation. In the Nass trial, fasting blood glucose rose by roughly 5 milligrams per decilitre on MK-677 and insulin sensitivity decreased. The mechanism is not incidental, it is the point. Growth hormone directly opposes insulin, so keeping growth hormone elevated around the clock, which is precisely what once-daily MK-677 does, pushes fasting glucose up and makes the body's tissues respond less well to insulin. In a healthy person this may register as a small, tolerable shift in blood work. In someone with prediabetes, diabetes, or a strong family history of it, the same mechanism is a real concern, because the drug is working against the exact system that is already struggling. Appetite is the other predictable effect, since MK-677 acts on the ghrelin receptor, and ghrelin is a hunger signal. The increased appetite can be useful for people trying to gain weight and unwelcome for people trying not to. Neither the glucose effect nor the appetite effect is a side reaction that better dosing removes. Both are direct consequences of the mechanism that makes the drug do anything at all.
The Metabolic Cost That Came With It
Mean change in fasting blood glucose on the trial. Fasting glucose rose by roughly 5 milligrams per decilitre on MK-677, and insulin sensitivity fell. Sustained growth hormone elevation antagonizes insulin, so higher fasting glucose is the predictable price of keeping the growth hormone axis switched on. For anyone with prediabetes or diabetes this is the finding that matters most, and it is why the effect is treated as a caution rather than a footnote.
Who Was MK-677 Actually Studied In, and Who Wasn't?
The best MK-677 data comes from older adults and frail patients, not from young athletes, and that gap matters. The two-year study enrolled healthy people aged 60 to 81, and the functional trial enrolled elderly hip-fracture patients. Both groups were chosen because they had age-related declines in growth hormone and lean mass that the drug might plausibly reverse. Almost none of the controlled evidence describes what MK-677 does in a healthy 30-year-old training hard, which is the person most likely to buy it. Extending results from a 70-year-old who has lost muscle to a young lifter who is actively building it is an inference the trials do not support in either direction. It is possible the drug behaves differently in a young trained body, and it is possible the same ceiling on strength shows up there too. The studies simply were not run in that population, over the durations people actually use it, at the doses sold online. The mass-and-metabolism findings are probably directional across ages because they follow from the mechanism, but the specific numbers belong to the people who were enrolled, and honesty about that boundary is part of reading the evidence correctly.
How Should the Whole Body of Evidence Be Read?
Put every measured outcome on one axis and MK-677 reads as a drug that does precisely what its mechanism predicts and nothing it was hoped to do beyond that. Growth hormone and IGF-1 rise substantially and reliably. Fat-free mass increases by a modest amount, part of it water. Appetite increases. Fasting glucose rises and insulin sensitivity falls. Muscle strength and physical function do not improve to a degree the trials could confirm, across two studies in two populations. None of that is contradictory once the mechanism is clear, because MK-677 raises the hormonal inputs to muscle without supplying the one input that actually builds force, which is training under load. What is established is the hormonal effect, the modest body-composition effect, and the metabolic cost. What is not established is any reliable gain in strength, function, or long-term health outcome, and what is entirely unstudied is the safety of taking a compound that keeps growth hormone elevated for years, since sustained IGF-1 elevation carries theoretical risks that no long-term human trial has resolved. MK-677 is not FDA-approved for any use and is sold as a research chemical without the oversight that applies to medicines. The reasonable reading has nothing to do with buying anything: the drug's advertised identity as a muscle and strength builder is the part its own trials support least, the metabolic tradeoff is real and follows anyone who takes it, and questions about long-term use belong with a clinician who can see the labs. This article is educational and describes published trial data. It is not a protocol and not a recommendation to start or stop any compound.
The Whole Body of Evidence on One Axis
Every headline effect of MK-677 arranged as a single schematic map. Teal bars are documented benefits, amber bars are the metabolic cautions that travel with them, and the grey bar is the outcome that did not move. Bar length is a rough visual weight rather than a shared unit, so this is a guide to where the evidence is strong and where it is thin, not a scoreboard. The pattern is consistent across the trials: MK-677 reliably changes hormones and body composition, reliably changes appetite and blood sugar, and does not reliably change strength.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.